| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,320,000 |
| Market
Cap: |
3.58(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$57.42 - $97.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
56,985 |
56,985 |
86,573 |
86,573 |
| Total Sell Value |
$4,162,391 |
$4,162,391 |
$6,386,821 |
$6,386,821 |
| Total People Sold |
2 |
2 |
3 |
3 |
| Total Sell Transactions |
3 |
3 |
5 |
5 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Saad Mark E |
Director |
– • – |
2019-05-23 |
4 |
B |
$22.33 |
$78,155 |
D/D |
3,500 |
7,002 |
2.39 |
- |
|
| Coleman Mark |
Director |
– • – |
2019-05-13 |
4 |
B |
$21.44 |
$99,696 |
D/D |
4,650 |
652,648 |
2.39 |
- |
|
| Pizzie Nick |
Chief Financial Officer |
• – – |
2019-03-19 |
4 |
B |
$12.58 |
$67,177 |
D/D |
5,340 |
36,340 |
2.74 |
- |
|
| Pizzie Nick |
Chief Financial Officer |
• – – |
2019-03-19 |
4 |
B |
$12.69 |
$761 |
I/I |
60 |
60 |
1.91 |
- |
|
| Coleman Mark |
Director |
– • – |
2019-03-19 |
4 |
B |
$12.18 |
$62,118 |
I/I |
5,100 |
5,100 |
2.1 |
- |
|
| Pizzie Nick |
Chief Financial Officer |
• – – |
2018-06-19 |
4 |
B |
$3.05 |
$96,080 |
D/D |
31,000 |
31,000 |
2.74 |
- |
|
| Jeffs Roger |
Director |
– • – |
2017-03-29 |
4 |
OE |
$3.67 |
$201,163 |
D/D |
42,538 |
46,912 |
|
- |
|
| Kaye Randall |
Chief Medical Officer |
• – – |
2015-12-23 |
4 |
B |
$9.03 |
$9,026 |
I/I |
1,000 |
6,022 |
1.99 |
- |
|
| Jeffs Roger |
Director |
– • – |
2015-11-24 |
4 |
OE |
$5.94 |
$25,982 |
D/D |
4,374 |
4,374 |
|
- |
|
| Coleman Mark |
Director |
– • – |
2015-11-24 |
4 |
OE |
$5.40 |
$3,224,166 |
D/D |
564,948 |
647,998 |
|
- |
|
| Tabuteau Herriot |
Chief Executive Officer |
• • • |
2015-11-24 |
4 |
OE |
$5.94 |
$42,940 |
D/D |
7,229 |
7,229 |
|
- |
|
| Saad Mark E |
Director |
– • – |
2015-11-24 |
4 |
OE |
$5.94 |
$20,802 |
D/D |
3,502 |
3,502 |
|
- |
|
| Kaye Randall |
Chief Medical Officer |
• – – |
2015-11-24 |
4 |
OE |
$5.40 |
$27,119 |
D/D |
5,022 |
5,022 |
|
- |
|
| Ames Constance |
Vice President, Finance |
• – – |
2015-11-24 |
4 |
OE |
$5.94 |
$25,887 |
D/D |
4,358 |
4,358 |
|
- |
|
| Antecip Capital Llc |
10% Owner |
– – • |
2015-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,344,500 |
|
- |
|
| Tabuteau Herriot |
Chief Executive OfficerOfficer |
• • • |
2015-11-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,344,500 |
|
- |
|
| Coleman Mark |
Director |
– • – |
2015-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,050 |
|
- |
|
42 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
3.14 (4.33%) 
